xenpozyme
sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - jiné zažívací trakt a produkty metabolismu, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.
vinpocetine covex 5mg tableta
covex s.a., madrid array - 3336 vinpocetin - tableta - 5mg - vinpocetin
vinpocetine covex s.a. 10mg tableta
covex s.a., madrid array - 3336 vinpocetin - tableta - 10mg - vinpocetin
vinpocetine covex s.a. 5mg tableta
covex s.a., madrid ŠpanĚlsko - 3336 vinpocetin - tableta - 5mg - vinpocetin
cavinton 5mg/ml injekční roztok
gedeon richter plc., budapešť array - 3336 vinpocetin - injekční roztok - 5mg/ml - vinpocetin
cavinton 5mg tableta
gedeon richter plc., budapešť array - 3336 vinpocetin - tableta - 5mg - vinpocetin
cavinton forte 10mg tableta
gedeon richter plc., budapešť array - 3336 vinpocetin - tableta - 10mg - vinpocetin
neparvis
novartis europharm limited - sacubitril, valsartan - srdeční selhání - agens působící na systém renin-angiotenzin - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
invokana
janssen-cilag international nv - kanagliflozin - diabetes mellitus, typ 2 - léky užívané při diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5.
adrovance
n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporóza, postmenopauzální - léky na léčbu nemocí kostí - léčba postmenopauzální osteoporózy u pacientů s rizikem nedostatečnosti vitaminu d. přípravek adrovance snižuje riziko vertebrálních a kyčelních fraktur.